• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Tenaya Therapeutics Inc.

    2/3/26 4:06:14 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TNYA alert in real time by email
    S-8 1 tnya-20260202.htm S-8 S-8

    As filed with the Securities and Exchange Commission on February 3, 2026

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER THE SECURITIES ACT OF 1933

    TENAYA THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware

    81-3789973

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification Number)

     

    171 Oyster Point Boulevard, Suite 500

    South San Francisco, CA 94080

    (650) 825-6990

    (Address, including zip code, and telephone number, including area code, of Registrant’s principal executive offices)

     

    2021 Equity Incentive Plan

    2021 Employee Stock Purchase Plan

    2024 Inducement Equity Incentive Plan

    (Full title of the plan)

     

    Faraz Ali, M.B.A.

    Chief Executive Officer

    Tenaya Therapeutics, Inc.

    171 Oyster Point Boulevard, Suite 500

    South San Francisco, CA 94080

    (650) 825-6990

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

    Jennifer Knapp

    Emily A. Coskey

    Wilson Sonsini Goodrich & Rosati

    Professional Corporation

    650 Page Mill Road

    Palo Alto, CA 94304

    (650) 493-9300

    Jennifer Drimmer Rokovich

    General Counsel

    Tenaya Therapeutics, Inc.

    171 Oyster Point Boulevard, Suite 500

    South San Francisco, California 94080

    (650) 825-6990

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

     

     

     

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

     

     

     

     

    Non-accelerated filer

    ☒

    Smaller reporting company

    ☒

     

     

     

     

     

     

    Emerging growth company

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     


     

    PART I

    EXPLANATORY NOTE

    This Registration Statement on Form S-8 (Registration Statement) is filed by Tenaya Therapeutics, Inc. (Registrant) for the purpose of registering 4,000,000 shares of common stock of the Registrant reserved for issuance under the 2021 Equity Incentive Plan, 800,000 shares of common stock of the Registrant reserved for issuance under the 2021 Employee Stock Purchase Plan, and 2,161,000 additional shares of common stock of the Registrant reserved for issuance under the 2024 Inducement Equity Incentive Plan.

    INFORMATION REQUIRED IN THE PROSPECTUS

    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3.

    Incorporation of Documents by Reference.

    The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed with the Securities and Exchange Commission (Commission):

    (a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 10, 2025 pursuant to Section 13(a) of the Securities Exchange Act of 1934, as amended (Exchange Act); and

    (b) All other reports filed with the Commission pursuant to Sections 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant’s Annual Report referred to in (a) above; and

    (c) The description of the Registrant’s Common Stock contained in the Company’s Registration Statement on Form 8-A (File No. 001-40656) filed with the Commission on July 23, 2021, pursuant to Section 12(b) of Exchange Act, including any amendment or report filed for the purpose of updating such description.

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with the rules of the Commission shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Item 4.

    Description of Securities.

    Not applicable.

    Item 5.

    Interests of Named Experts and Counsel.

    Not applicable.

    Item 6.

    Indemnification of Directors and Officers.

    Section 145 of the Delaware General Corporation Law generally empowers a corporation to indemnify its directors and officers, provided that the person acted in good faith and in a manner the person reasonably believed to be in our best interests, and, with respect to any criminal action, had no reasonable cause to believe the person’s actions were unlawful, and to purchase insurance with respect to liability arising out of their capacity or status as directors and officers. The Delaware General Corporation Law further provides that the indemnification permitted thereunder shall not be deemed exclusive of any other rights to which the directors and officers may be entitled under the corporation’s bylaws, any agreement, a vote of stockholders or otherwise. The amended and restated certificate of incorporation of the Registrant provides for the


    indemnification of the Registrant’s directors and officers to the fullest extent permitted under the Delaware General Corporation Law.

    In addition, the amended and restated bylaws of the Registrant require, subject to certain limitations, the Registrant to fully indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (whether civil, criminal, administrative or investigative) by reason of the fact that such person is or was a director or officer of the Registrant, or is or was a director or officer of the Registrant serving at the Registrant’s request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorney’s fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, to the fullest extent permitted by applicable law.

    Section 102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director or an officer of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, except (1) for any breach of the director’s or officer’s duty of loyalty to the corporation or its stockholders, (2) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (3) for payments of unlawful dividends or unlawful stock repurchases or redemptions, (4) for any transaction from which the director or officer derived an improper personal benefit, or (5) with respect to an officer, in any action by or in the right of the corporation. The Registrant’s amended and restated certificate of incorporation provides that the Registrant’s directors and officers shall not be personally liable to it or its stockholders for monetary damages for breach of fiduciary duty as a director or officer and that if the Delaware General Corporation Law is amended to authorize corporate action further eliminating or limiting the personal liability of directors or officers, then the liability of the Registrant’s directors and officers shall be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law, as so amended.

    Section 174 of the Delaware General Corporation Law provides, among other things, that a director who willfully or negligently approves of an unlawful payment of dividends or an unlawful stock repurchase or redemption may be held liable to the full amount of the dividend unlawfully paid, or to the full amount unlawfully paid for the repurchase or redemption of the corporation’s stock, with interest from the time such liability accrued. A director who was either absent when the unlawful actions were approved, or dissented at the time, may avoid liability by causing his or her dissent to such actions to be entered in the books containing minutes of the proceedings of the board of directors at the time such action occurred or immediately after such absent director receives notice of the unlawful acts.

    As permitted by the Delaware General Corporation Law, the Registrant has entered into separate indemnification agreements with each of the Registrant’s directors and executive officers which would require the Registrant, among other things, to indemnify them against certain liabilities which may arise by reason of their status as directors or executive officers.

    The Registrant has obtained insurance policies under which its directors and officers are insured, within the limits and subject to the limitations of those policies, against certain expenses in connection with the defense of, and certain liabilities which might be imposed as a result of, actions, suits or proceedings to which they are parties by reason of being or having been directors or officers. The coverage provided by these policies may apply whether or not the Registrant would have the power to indemnify such person against such liability under the provisions of the Delaware General Corporation Law.

    These indemnification provisions and the indemnification agreements entered into between the Registrant and the Registrant’s officers and directors may be sufficiently broad to permit indemnification of the Registrant’s officers and directors for liabilities (including reimbursement of expenses incurred) arising under the Securities Act of 1933, as amended.

    Item 7.

    Exemption from Registration Claimed.

    Not applicable.


    Item 8.

    Exhibits.

     

     

     

     

     

     

     

     

     

     

     

     

     

    Exhibit

    Number

    Incorporated by Reference

    Description

    Form

    File No.

    Exhibit

    Filing Date

     

     

     

     

     

     

    4.1

    Specimen common stock certificate of the Registrant

    S-1/A

    333-257820

    4.2

    7/26/2021

     

     

     

     

     

     

    4.2

    2021 Equity Incentive Plan and forms of agreements thereunder

    10-K

    001-40656

    10.2

    3/23/2022

     

     

     

     

     

     

    4.3

    2021 Employee Stock Purchase Plan and forms of agreements thereunder

    S-1/A

    333-257820

    10.4

    7/26/2021

     

     

     

     

     

     

    4.4

     

    2024 Inducement Equity Incentive Plan, as amended, and forms of agreements thereunder

     

    8-K

     

    001-40656

     

    10.1

     

    1/30/2026

     

     

     

     

     

     

     

     

     

     

     

     

     

    5.1*

    Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation

     

     

     

     

     

     

     

     

     

     

     

     

     

    23.1*

    Consent of Deloitte and Touche LLP, Independent Registered Public Accounting Firm

     

     

     

     

     

     

     

     

     

     

     

     

     

    23.2*

    Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (contained in Exhibit 5.1 hereto)

     

     

     

     

     

     

     

     

     

     

     

     

     

    24.1*

    Power of Attorney (contained on signature page hereto)

     

     

     

     

     

     

     

     

     

     

     

     

     

    107*

    Filing Fee Table

     

     

     

     

     

     

     

    *

    Filed herewith.

     

    Item 9.

    Undertakings.

    A.

    The undersigned Registrant hereby undertakes that:

    (1)

    It will file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i)

    To include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii)

    To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

    (iii)

    To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.

    Provided, however, that paragraphs (A)(1)(i) and (A)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

    (2)

    For the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3)

    It will remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     


    B.

    The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    C.

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer, or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, California, on February 3, 2026.

     

     

     

    TENAYA THERAPEUTICS, INC.

     

     

    By:

    /s/ Faraz Ali, M.B.A.

     

    Faraz Ali, M.B.A.

     

    Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Faraz Ali as his or her true and lawful attorneys-in-fact and agents, with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities to sign this Registration Statement and any and all amendments thereto (including post-effective amendments), and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as they, he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agents or any of them, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

     

     

     

     

     

    Signature

    Title

    Date

     

     

     

    /s/ Faraz Ali, M.B.A.

    Chief Executive Officer and Director

    (Principal Executive Officer and Interim Principal Financial Officer)

    February 3, 2026

    Faraz Ali, M.B.A.

     

     

     

    /s/ Tomohiro Higa, M.B.A.

      Senior Vice President, Finance

    February 3, 2026

    Tomohiro Higa, M.B.A.

      (Interim Principal Accounting Officer)

     

     

     

     

    /s/ Amy Burroughs, M.B.A.

    Director

    February 3, 2026

    Amy Burroughs, M.B.A.

     

     

     

    /s/ June Lee, M.D.

    Director

    February 3, 2026

    June Lee, M.D.

     

     

     

     

     

    /s/ Karah Parschauer, J.D.

    Director

    February 3, 2026

    Karah Parschauer, J.D.

     

     

     

     

     

     

     

     

     

    /s/ Deepak Srivastava, M.D.

    Director

    February 3, 2026

    Deepak Srivastava, M.D.

     

     

     

     

     

     

     

     

     

    /s/ Catherine Stehman-Breen, M.D.

    Director

     February 3, 2026

    Catherine Stehman-Breen, M.D.

     

     

     

     

     

     

     

     

     

    /s/ Jeffrey T. Walsh, M.B.A.

    Director

      February 3, 2026

    Jeffrey T. Walsh, M.B.A.

     

     

     

     

     

     

     

     

     

    /s/ R. Sanders (Sandy) Williams, M.D.

    Director

     February 3, 2026

    R. Sanders (Sandy) Williams, M.D.

     

     

     

     

     


     


    Get the next $TNYA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TNYA

    DatePrice TargetRatingAnalyst
    6/10/2024Outperform
    William Blair
    11/30/2023$7.00Outperform
    Leerink Partners
    6/15/2022$25.00Buy
    H.C. Wainwright
    8/24/2021Outperform
    Cowen & Co.
    8/24/2021$31.00Overweight
    Morgan Stanley
    8/24/2021$37.00Buy
    Chardan Capital
    8/24/2021$40.00Overweight
    Piper Sandler
    More analyst ratings

    $TNYA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones

    Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 Trial of Adults with MYBPC3-Associated HCM Expects to Report One-Year Cohort 1 Data and Early Cohort 2 Data from RIDGE™-1 Study of TN-401 for PKP2-Associated ARVC in First Half of 2026 Plans to Pursue Alignment on Regulatory Pathways for Lead Gene Therapy Programs in 2026 Raised $60 Million in 4Q25 to Support Runway Through mid-2027 SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative th

    1/9/26 8:30:00 AM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tenaya Therapeutics Announces Pricing of Public Offering

    SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the pricing of its underwritten public offering of 50,000,000 total units for gross proceeds of $60 million prior to deducting underwriting discounts and commissions and offering expenses.  Tenaya intends to use the net proceeds from the offering to fund the ongoing and planned development of its clinical and early-stage product candidates, particularly TN-201 and TN-401, and for working capital and oth

    12/12/25 12:16:53 AM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tenaya Therapeutics Announces Proposed Public Offering

    SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it intends to offer and sell units consisting of common stock and warrants to purchase shares of common stock. Tenaya may also sell to certain investors, in lieu of units, pre-funded units consisting of pre-funded warrants to purchase shares of common stock at a purchase price of $0.001 per share and warrants to purchase shares of common stock. The pre-funded warrants will be immediately exercisable

    12/11/25 4:02:00 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TNYA
    SEC Filings

    View All

    SEC Form S-8 filed by Tenaya Therapeutics Inc.

    S-8 - Tenaya Therapeutics, Inc. (0001858848) (Filer)

    2/3/26 4:06:14 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tenaya Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update, Financial Statements and Exhibits

    8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)

    1/30/26 5:06:08 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tenaya Therapeutics Inc. filed SEC Form 8-K: Leadership Update

    8-K - Tenaya Therapeutics, Inc. (0001858848) (Filer)

    1/2/26 5:10:33 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TNYA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Finance Higa Tomohiro sold $1,818 worth of shares (1,367 units at $1.33), decreasing direct ownership by 1% to 93,971 units (SEC Form 4)

    4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

    11/17/25 8:34:59 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Medical Officer Tingley Whittemore sold $3,826 worth of shares (2,877 units at $1.33), decreasing direct ownership by 2% to 169,926 units (SEC Form 4)

    4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

    11/17/25 8:34:13 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Ali Faraz sold $4,158 worth of shares (3,126 units at $1.33), decreasing direct ownership by 1% to 299,666 units (SEC Form 4)

    4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

    11/17/25 8:33:38 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TNYA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Tenaya Therapeutics

    William Blair initiated coverage of Tenaya Therapeutics with a rating of Outperform

    6/10/24 7:25:34 AM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Leerink Partners initiated coverage on Tenaya Therapeutics with a new price target

    Leerink Partners initiated coverage of Tenaya Therapeutics with a rating of Outperform and set a new price target of $7.00

    11/30/23 7:50:26 AM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Tenaya Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Tenaya Therapeutics with a rating of Buy and set a new price target of $25.00

    6/15/22 7:41:04 AM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TNYA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Column Group Iii Gp, Lp bought $24,999,999 worth of shares (35,714,284 units at $0.70) (SEC Form 4)

    4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

    3/7/25 7:14:40 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Goeddel David V bought $24,999,999 worth of shares (35,714,284 units at $0.70) (SEC Form 4)

    4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

    3/7/25 7:14:15 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Column Group Iii Gp, Lp bought $9,999,999 worth of shares (2,222,222 units at $4.50) (SEC Form 4)

    4 - Tenaya Therapeutics, Inc. (0001858848) (Issuer)

    2/14/24 4:15:53 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TNYA
    Financials

    Live finance-specific insights

    View All

    Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC

    TN-401 was Well Tolerated at 3E13 vg/kg dose  Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8 Clinically Meaningful Reductions in Arrhythmia Burden Observed in First Two Patients with More Than Six Months of Follow-Up Tenaya Management to Host a Webcast Conference Call Thursday, December 11 at 5:00 pm ET to Review Preliminary Results SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced interim data

    12/11/25 4:01:00 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

    Presentation of MyPEAK-1 Data and the American Heart Association Scientific Sessions Showed Consistent, Deeper, and Durable Improvement in Measures of Hypertrophy for Cohort 1 Patients Initial TN-201 Cohort 2 Data Demonstrated Early Dose Responsive Increases in TN-201 Transduction and MyBP-C Protein Expression Completed Dosing in Cohort 2 of RIDGE™-1 Trial of TN-401 for PKP2-associated ARVC; Cohort 1 Data On Track for Fourth Quarter Company Presentation Tenaya Management to Review New MyPEAK-1 Data on Webcast Call for Analysts and Investors Today at 8:00 a.m. EST SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage bi

    11/10/25 7:00:00 AM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

    MyPEAK-1 Data Presented During Late-Breaking Session at AHA Scientific Sessions 2025 with Simultaneous Publication in Cardiovascular Research TN-201 Has Been Generally Well Tolerated at Both Doses Longer-term Follow Up of Cohort 1 Patients Showed Consistent, Deeper, and Durable Improvement in Measures of Hypertrophy Initial Cohort 2 Data Demonstrated Early Dose Responsive Increases in TN-201 Transduction and MyBP-C Protein Expression Tenaya Management to Host Webcast Call for Analysts and Investors on Monday, November 10 at 8:00 a.m. EST NEW ORLEANS and SOUTH SAN FRANCISCO, Calif., Nov. 08, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA) announced that new interim s

    11/8/25 11:25:00 AM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TNYA
    Leadership Updates

    Live Leadership Updates

    View All

    Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

    Enrollment Complete in Cohorts 1 and 2 of MyPEAK™-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts Cohort 1 of RIDGE™-1 Phase 1b Trial of TN-401 Enrolled and First PKP2-associated ARVC Patient Dosed in Cohort 2 Following DSMB Recommendation to Dose Escalate and Expand Data Readouts from Both TN-201 and TN-401 Clinical Programs Planned for the Fourth Quarter of 2025 Cash Runway into Second Half of 2026 SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potent

    8/6/25 4:30:00 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Oxford Biomedica Appoints Leone Patterson as Non-Executive Director

    Oxford Biomedica Appoints Leone Patterson as Non-Executive Director Oxford, UK – 26th April 2023: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the Company"), a quality and innovation-led viral vector CDMO, today announces the appointment of Ms Leone Patterson as an Independent Non-Executive Director. Ms Patterson shall join the Board on 1st May 2023. Ms Patterson has more than 20 years of public company biotech experience including in the cell and gene therapy industry and has managed significant growth within international commercial companies working across areas including strategy, finance, operations and governance. She is currently the Chief Financial and Business Officer a

    4/26/23 7:00:00 AM ET
    $NKTX
    $TNYA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors

    SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the appointment of Amy Burroughs to its Board of Directors. Ms. Burroughs currently serves as President and Chief Executive Officer of Cleave Therapeutics, a clinical-stage company focused on developing novel medicines for oncology and neurodegenerative diseases. "We are pleased to welcome Ms. Burroughs to the Tenaya Board. Her substantial and diverse industry experience in the development and commercia

    12/7/22 4:30:00 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TNYA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tenaya Therapeutics Inc.

    SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

    11/14/24 5:46:12 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tenaya Therapeutics Inc.

    SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

    11/14/24 1:22:39 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Tenaya Therapeutics Inc. (Amendment)

    SC 13G/A - Tenaya Therapeutics, Inc. (0001858848) (Subject)

    2/14/24 5:01:36 PM ET
    $TNYA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care